Prime Medicine doses first patient in Wilson disease gene editing trial
Tweet Send to a Friend
Prime Medicine, Inc. (Nasdaq: PRME) announced that the first patient has been dosed in its global Phase 1/2 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




